These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16224447)

  • 41. Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
    Salzberg M; Thurlimann B; Bonnefois H; Fink D; Rochlitz C; von Moos R; Senn H
    Oncology; 2005; 68(4-6):293-8. PubMed ID: 16020955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
    Ramirez PT; Schmeler KM; Milam MR; Slomovitz BM; Smith JA; Kavanagh JJ; Deavers M; Levenback C; Coleman RL; Gershenson DM
    Gynecol Oncol; 2008 Jul; 110(1):56-9. PubMed ID: 18457865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy in epithelial ovarian cancer.
    Wang J; Li AJ; Karlan BY
    Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
    Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
    J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salvage therapy for ovarian cancer.
    Sabbatini P; Spriggs D
    Oncology (Williston Park); 1998 Jun; 12(6):833-43; discussion 844-6, 848, 851. PubMed ID: 9644684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
    Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ovarian cancer as a chronic disease: a new treatment paradigm. Highlights of a roundtable discussion.
    Spriggs DR
    Cancer Control; 2001; 8(6 Suppl 1):5-7; discussion 8-18. PubMed ID: 11910332
    [No Abstract]   [Full Text] [Related]  

  • 51. Ovarian cancer: relevant therapy, not timing, is paramount.
    Morris RT; Monk BJ
    Lancet; 2010 Oct; 376(9747):1120-2. PubMed ID: 20888975
    [No Abstract]   [Full Text] [Related]  

  • 52. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Lairson DR; Parikh RC; Cormier JN; Du XL
    Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
    Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
    Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 56. Targeted therapies for treatment of recurrent ovarian cancer.
    Grisham RN; Hyman DM; Iyer G
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer.
    Le T; Hopkins L; Kee Fung MF
    Gynecol Oncol; 2005 Jul; 98(1):39-44. PubMed ID: 15907986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvage treatment of ovarian cancer.
    Muggia FM
    J Clin Oncol; 1997 Nov; 15(11):3420-1. PubMed ID: 9363877
    [No Abstract]   [Full Text] [Related]  

  • 59. NCCN: New chemotherapeutic approaches to hormone refractory prostate cancer.
    Carducci MA;
    Cancer Control; 2001; 8(6 Suppl 2):62-5. PubMed ID: 11760560
    [No Abstract]   [Full Text] [Related]  

  • 60. Recurrent small cell carcinoma of the ovary treated with docetaxel: A case report.
    Niimi S; Kiyokawa T; Takakura S; Ochiai K; Tanaka T
    Int J Gynecol Cancer; 2006; 16(5):1944-6. PubMed ID: 17009997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.